| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMP038168 |
| P698 | PubMed publication ID | 14681501 |
| P2093 | author name string | Bevra Hannahs Hahn | |
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 2379-2380 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Systemic lupus erythematosus and accelerated atherosclerosis | |
| P478 | volume | 349 |
| Q58052135 | A Functional Ser413/Ser413 PAI-2 Polymorphism Is Associated With Susceptibility and Damage Index Score in Systemic Lupus Erythematosus |
| Q34897464 | Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus |
| Q30481548 | Arterial distensibility in chronic inflammatory rheumatic disorders |
| Q44586620 | Atheroma and auto-immunity: 50th congress of the National French Society of Internal Medicine |
| Q53039592 | Early evaluation of carotid elasticity by an instantaneous wave intensity technique in patients with systemic lupus erythematosus. |
| Q43417859 | Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. |
| Q35016981 | HDAC inhibition in lupus models |
| Q51651321 | Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. |
| Q33374874 | Hughes Syndrome: the antiphospholipid syndrome--a clinical overview |
| Q64093737 | Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies |
| Q39600465 | Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus |
| Q51735851 | Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. |
| Q43654377 | Is there a 'window of opportunity' for intervention to reduce risk of coronary artery disease in SLE? |
| Q26775996 | MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives |
| Q36082627 | Manifestations of systemic lupus erythematosus |
| Q36085841 | Mechanisms of action of mycophenolate mofetil |
| Q43275139 | Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. |
| Q46404846 | Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain |
| Q40297850 | Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients |
| Q36054872 | Optimal care of lupus nephritis patients |
| Q53196713 | Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. |
| Q37777642 | Prevalence and burden of pediatric-onset systemic lupus erythematosus |
| Q34500527 | Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis |
| Q47549484 | Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. |
| Q34017775 | Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study |
| Q40461525 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. |
| Q53194239 | Systemic lupus erythematosus risk factors for coronary artery calcifications. |
| Q26779929 | The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms |
| Q37817582 | The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? |
| Q34027495 | Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis |
| Q38663003 | Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. |
| Q36130959 | Vasculitis: mechanisms involved and clinical manifestations |
| Q44688452 | What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus? |
| Q84600129 | [Antimalarials: an update in rheumatic diseases] |
| Q81057481 | [Systemic lupus erythematosus and accelerated atheromatosis] |
| Q79566794 | [The heart in rheumatic diseases] |
Search more.